Biblio Discovery — Demo Discovery Service

13 hasil untuk "Matteo Repetto"

Menampilkan 1–13 · 0,64 detik · RSS

  1. Artikel Jurnal

    Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion‐driven non‐small cell lung cancer

    Antoine Desilets; Matteo Repetto; Alexander Drilon

    Clinical and Translational Medicine, Vol. 14 No. 10 · 2024 · Inggris · DOAJ Scopus

    Abstract The ROS1 proto‐oncogene encodes a receptor tyrosine kinase with structural homology to other oncogenic drivers, including ALK and TRKA‐B‐C. The FDA‐approved tyrosine kinase inhibitors (TKIs) crizotinib and entrectinib have demonstrated efficacy in treating ROS1 fusion‐positive NSCLC…

  2. Artikel Jurnal Teks lengkap

    Improving Efficiency of Edge Computing Infrastructures through Orchestration Models †

    Raffaele Bolla; Alessandro Carrega; Matteo Repetto dkk.

    Computers, Vol. 7 No. 2 · 2018 · Inggris · DOAJ Scopus

    Edge computing is an effective paradigm for proximity in computation, but must inexorably face mobility issues and traffic fluctuations. While software orchestration may provide effective service handover between different edge infrastructures, seamless operation with negligible service disruption…

  3. Artikel Jurnal Teks lengkap

    Advantages of Using Supercapacitors and Silicon Carbide on Hybrid Vehicle Series Architecture

    Massimiliano Passalacqua; Damiano Lanzarotto; Matteo Repetto dkk.

    Energies, Vol. 10 No. 7 · 2017 · Inggris · DOAJ Scopus

    In recent years enormous growth has taken place in the hybrid vehicle sector; parallel architecture is the most widespread configuration regarding medium size cars. At the same time, storage systems and power electronics have experienced some important innovations. The development of…

  4. Artikel Jurnal Teks lengkap

    Turbocompound Power Unit Modelling for a Supercapacitor-Based Series Hybrid Vehicle Application

    Matteo Repetto; Massimiliano Passalacqua; Luis Vaccaro dkk.

    Energies, Vol. 13 No. 2 · 2020 · Inggris · DOAJ Scopus

    In this paper, starting from the measurements available for a 2000 cm3 turbocharged diesel engine, an analytical model of the turbocharger is proposed and validated. The model is then used to extrapolate the efficiency of a power unit with a diesel engine combined with a turbocompound system. The…

  5. Artikel Jurnal Teks lengkap

    Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies

    Gabriele Antonarelli; Federica Giugliano; Chiara Corti dkk.

    Pharmaceuticals, Vol. 14 No. 9 · 2021 · Inggris · DOAJ Scopus

    Solid tumors adopt multiple mechanisms to grow, evade immune responses, and to withstand therapeutic approaches. A major breakthrough in the armamentarium of anti-cancer agents has been the introduction of monoclonal antibodies (mAbs), able to inhibit aberrantly activated pathways and/or to unleash…

  6. Artikel Jurnal Teks lengkap

    Electrical-Loss Analysis of Power-Split Hybrid Electric Vehicles

    Andrea Bonfiglio; Damiano Lanzarotto; Mario Marchesoni dkk.

    Energies, Vol. 10 No. 12 · 2017 · Inggris · DOAJ Scopus

    The growing development of hybrid electric vehicles (HEVs) has seen the spread of architectures with transmission based on planetary gear train, realized thanks to two electric machines. This architecture, by continuously regulating the transmission ratio, allows the internal combustion engine…

  7. Artikel Jurnal Teks lengkap

    Supercapacitor Storage Sizing Analysis for a Series Hybrid Vehicle

    Massimiliano Passalacqua; Mauro Carpita; Serge Gavin dkk.

    Energies, Vol. 12 No. 9 · 2019 · Inggris · DOAJ Scopus

    The increasing interest in Hybrid Electric Vehicles led to the study of new powertrain structures. In particular, it was demonstrated in the technical literature how series architecture can be more efficient, compared to parallel one, if supercapacitors are used as storage system. Since…

  8. Artikel Jurnal

    TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers

    Rajat Thawani; Matteo Repetto; Clare Keddy dkk.

    npj Precision Oncology, Vol. 8 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract ROS1 tyrosine kinase inhibitors (TKIs) are highly effective in ROS1-positive non-small cell lung cancer, but resistance remains a challenge. We investigated the activity of various TKIs against wildtype and mutant ROS1, focusing on the emerging L2086F resistance mutation. Using Ba/F3 and…

  9. Artikel Jurnal

    Breast carcinomas associated with microglandular adenosis are linked to germline alterations in homologous recombination-deficiency genes

    Christopher J. Schwartz; Iskender Genco; Matteo Repetto dkk.

    npj Breast Cancer, Vol. 11 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Invasive breast carcinomas associated with microglandular adenosis (IBC-MGA) represent a rare and poorly characterized form of triple-negative breast cancer (TNBC). We analyzed clinical, pathological, and germline genetic data from 38 patients, including 34 IBC-MGAs and 4 in situ cases…

  10. Artikel Jurnal

    Genomic landscape of breast cancer in elderly patients

    Pier Selenica; Higinio Dopeso; Matteo Repetto dkk.

    npj Breast Cancer, Vol. 11 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Breast cancer (BC) displays age-related histopathologic and transcriptomic heterogeneity. Whether BC in elderly patients differs genetically from that of younger individuals remains unclear. We re-analyzed sequencing data from 1918 BCs previously subjected to an FDA-cleared paired…

  11. Artikel Jurnal

    Responsiveness of different MET tumour alterations to type I and type II MET inhibitors

    Yonina R. Murciano‐Goroff; Valentina Foglizzo; Jason Chang dkk.

    Clinical and Translational Medicine, Vol. 15 No. 5 · 2025 · Inggris · DOAJ Scopus

    Abstract Background Mutations in c‐MET receptor tyrosine kinase (MET) can be primary oncogenic drivers of multiple tumour types or can be acquired as mechanisms of resistance to therapy. MET tyrosine kinase inhibitors (TKIs) are classified as type I or type II inhibitors, with the former binding to…